Clinical Trial · NCT07928037

A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients

Overview

This study aims to assess real-world clinical outcomes among adult metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with and progressed on an androgen receptor pathway inhibitor (ARPI) who received 177Lu-PSMA-617 as a monotherapy or with concurrent ARPI. The study will use secondary data taken from a United States oncology database.

Sponsor

Novartis

ClinicalTrials.gov

NCT07928037

Study contact

Novartis Pharmaceuticals

Novartis Pharmaceuticals Study director

Drug / Compound

PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • Evidence of pre-index exposure to an ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide) in the metastatic setting
  • Evidence of initiating a 177Lu-PSMA-617-containing LOT with or without a second-generation ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide) in mCRPC setting between 23 March 2022 and 31 October 2025, with concurrent therapies limited to androgen deprivation therapy (ADT) and/or 1st-generation antiandrogens only, and no other concurrent therapies permitted.
  • evidence of a progression date (per the database's real-world progression-free survival (rwPFS) variables), during or after the preceding ARPI LOT
  • Patients may not receive a clinical study drug (CSD) any time prior to 177Lu-PSMA-617-containing LOT.
  • At least 6 months of potential minimum follow-up from the first 177Lu-PSMA-617-containing LOT
  • At least two documented clinic visits on different days in the database network occurring on or after January 1, 2011.
  • Has an International Classification of Diseases (ICD) diagnosis of prostate cancer (ICD-9 185x; ICD-10 C61x)
  • Histology of Adenocarcinoma or prostate cancer, not otherwise specified (NOS).
  • Diagnosis of mCRPC
  • Evidence of ARPI progression on the ARPI line of treatment (LOT) immediately preceding 177Lu-PSMA-617 initiation, defined as
  • a castration-resistant prostate cancer (CRPC) date occurring during or after the preceding ARPI LOT
  • Has evidence of prostate cancer with an initial or metastatic diagnosis date, as identified by a machine learning (ML) model from unstructured documents.

Exclusion

  • Evidence of unknown histology.
  • Applied to ARPI-experienced mCRPC patient cohort:Individuals will be excluded if they meet any of the following criteria:
  • Patients enrolled in clinical trials at the time of 177Lu-PSMA-617 initiation.